# WEBINAR PRESENTATION

2<sup>nd</sup> QUARTER 2019





# 2<sup>nd</sup> QUARTER





## SALES IN 2<sup>nd</sup> QUARTER

Sales reached

**EUR 31.7 million** 

An increase by

2%

compared to Q2 2018

Net sales by pharmacies


= EUR 6.2 million

Net sales by Silvanols

= EUR 0.9 million

Net sales by Tonus Elast and Elast Medical

= EUR 2.2 million





## SALES IN 1st half of 2019 – new all-time record

Sales reached

EUR 66.4 million

An increase by

7%

compared to 1H 2018

Net sales by pharmacies


= EUR 12.6 million

Net sales by Silvanols

= EUR 2.1 million

Net sales by Tonus Elast and Elast Medical

= EUR 4.1 million






## CONTINUING GROWTH OF EBITDA AND MARGIN

**EBITDA** in the 1st half of 2019 was **EUR 17 million** that grew by 64%

EUR 26.8 million TTM EBITDA reached

TTM EBITDA margin further improved to 20.8%, from 19.8% last quarter

#### **Group's TTM EBITDA and EBITDA margin**





## STRONG NET PROFIT IN THE 2<sup>ND</sup> QUARTER OF 2019

Net profit of EUR 4 million, which is an increase by 49% y-o-y

Highest 2<sup>nd</sup> quarter profit since 2014

Net profit for the 1st half of 2019 was

**EUR 12.2 million**, by far the largest in Group's history




## **FACTORS AFFECTING NET PROFIT**


## Main factor contributing to the increase of net profit:

- \$\frac{1}{2}\$ Strong improvement in gross profit due to higher gross margin (61.9%, from 59.7%)
- ♣ Decline in marketing expenses (from 18.2 to 17 million EUR)
- ♣ Gains from favourable changes in Russian rouble rate (~2.7 million EUR)

Increase in administrative expenses from 11.4 to 13.6 million EUR negatively impacted net profit and was related to a rise in salaries and R&D expenses.



# POLL QUESTION





## SALES BY COUNTRIES, 1st half of 2019

Share of sales in TOP4 countries reached


77%

Latvia's share increased and Russia's share lost

## 1pp

- Share of sales in Ukraine decreased by 2pp and was 8% 1H, 2019
- The Netherlands are now the 5th largest market due to a renewed contract with the UN

#### SALES BREAKDOWN BY COUNTRIES, FIRST HALF OF 2019



## **GROWTH DRIVERS: COUNTRIES**

- Most of major markets are growing
- Largest growth in monetary terms added by Latvia (EUR 2.2m), the Netherlands (EUR 1.6m) and Russia (EUR 0.7m)
- Largest growth in relative terms provided by the Netherlands (729%), Tajikistan (42%) and Uzbekistan (37%)
- Biggest loss in monetary terms comes from the **Ukraine** (EUR 0.6m) and **Lithuania** (-EUR 0.35 m)
- ♣ Biggest loss in relative terms is in Lithuania (-33%), the Ukraine (-9%) and Germany (-5%)


#### Sales to Top 10 countries, 1H 2019 vs 1H 2018



www.olainfarm.com

## SALES BY PRODUCTS, 1st half of 2019

- Noofen's share rose by 1p.p. y-o-y and it remained **THE BESTSELLING PRODUCT**
- Neiromidin lost 1pp and Furamag/Furasol lost
  2pp but are still in TOP 3 product list
- PASS returned to the TOP 10 due to renewed supplies to the UN




\*Final dosage forms only




## **GROWTH DRIVERS: PRODUCTS**

- Out of the TOP 10 products nine are growing;
- The biggest growth in monetary terms added by PASS (1.6m), Noofen (0.8m) and Adaptol (0.5m);
- The biggest growth in relative terms provided by **PASS** (933%), **Remantadine** (121%) and **Furagin** (21%);

#### Bestselling Products, 1H 2019 vs 1H 2018, EUR '000



# POLL QUESTION





# UPDATE ON RECENT EVENTS






## **BORROWINGS**

- ABLV loan was refinanced by BlueOrange Bank:
  - Amount: 10.5 million EUR
  - Use of proceeds: refinancing and new investments
  - Duration: 5 years , full amortization
- Net Debt / EBITDA top limit is 2.3
- DSCR bottom limit is 1.5

#### **Group's TTM EBITDA and EBITDA margin**



## MANAGEMENT REMUNERATION

Total remuneration including all taxes for all members of Supervisory Council and Management Board

Quarter	Amount, EUR	Changes, q-o-q, EUR	Changes, q-o-q, %	Comment
1Q 2018	264 474	-	-	
2Q 2018	317 633	53 159	20%	Supervisory Council election
3Q 2018	497 512	179 879	57%	Supervisory Council election
4Q 2018	704 811	207 299	42%	
1Q 2019	717 556	12 745	2%	
2Q 2019	616 994	-100 562	-14%	Supervisory Council election

## **NEED A CAR?**

#### Start of a fully transparent process for the sale of luxury

#### vehicles:


- 3 BMW X5, BMW X5, BMW X1, BMW X4
- **MB** \$600, MB GLE 350
- Lexus NX 300

Total purchase cost was 386 thousand EUR



If interested please send a message olainfarm@olainfarm.com

# POLL QUESTION






### INVESTIGATION OF MARKETING EXPENSES

- Large-scale possibly fraudulent activity suspected in the use of the company's assets by former executives of JSC Olainfarm
- Marketing services raised doubts about their potential fictitious nature, economic validity and legitimacy
- The international auditor confirms that the transaction occurred, possibly causing losses to JSC Olainfarm
- Suspicious transactions occurred between 2 January, 2017 and 4 April, 2019
- Cooperation with the company has been completely suspended
- Criminal proceedings have been initiated by the police



## **NEW CEO**

- Olainfarm is looking to hire a new Chairman of the Management Board with international experience in the pharmaceutical industry
- A recruitment company Amrop Latvia has been engaged
- The process is planned to be completed by the end of October
- Lauris Macijevskis, current Chairman of the Management Board, will continue to be a member of the Board of JSC Olainfarm



## EGM ON NOVEMBER 1ST, 2019

- A request to convene an extraordinary general meeting of shareholders has been received from shareholder Ltd. "OLMAFARM":
  - Recall of the Council and Election of the new Council;
  - Recall of the Auditing committee and election of the new Auditing committee.
- Record date October 24th, 2019;
- Registration of shareholders will take place on the day of the meeting, i.e. November 1st, 2019, from 10:00 until 10:45 on the venue;
- Shareholder meeting starts at 11:00.

# Q&A SESSION









#### **Janis Dubrovskis**

Investor Relations Advisor



(+371) 67 013 705



janis.dubrovskis@olainfarm.com



www.olainfarm.com



Rupnicu iela 5, Olaine, LV-2114, Latvia